摘要
目的:观察奈达铂联合多西他赛治疗晚期非小细胞肺癌(non-smallcelllungcancer,NSCLC)的疗效和不良反应。方法:78例经病理和/或细胞学确诊的NSCLC患者,随机分成治疗组40例和对照组38例。治疗组采用奈达铂80mg/m2,静滴,d1。对照组采用顺铂25mg/m2,静滴,连续3d。两组均联合国产多西他赛75mg/m2,静滴d1;两种治疗方案均28天为1个周期。结果:治疗组和对照组治疗有效率分别为37.5%及42.1%,无明显统计学差异(P>0.05);治疗组胃肠道反应明显低于对照组(P<0.05);两组肝毒性无明显差异,但肾毒性治疗组较对照组低(P=0.05);两组白细胞下降发生率分别为37.5%及39.5%,无显著差异;血红蛋白下降率分别为47.5%及52.6%,无统计学差异;治疗组与对照组血小板下降率分别为47.5%及23.7%,具有统计学差异(P<0.05)。结论:治疗组与对照组的疗效基本接近,但治疗组胃肠道反应及肾毒性较轻,血小板的抑制率治疗组高于对照组外,血红蛋白及白细胞下降发生率无差异,奈达铂更易为医生和患者所接受。
Objective：To investigate the efficacy and side effects of the regimen of combined chemotherapy nedaplatin and docetaxel in the treatment of advanced non - small cell lung cancer. Methods ： A total of 78 patients with advanced non- small cell lung cancer diagnosed by the pathology and/or cytology were divided into the nedaplatin group （treatment group, n = 40） and cisplatin group （control group, n = 38 ）. Nedaplatin was given at 80mg/m^2 intravenously at the first day in the treatment group. Cisplatin was administrated at 25mg/m^2 intravenously for three days in the control group. Doeetaxel was infused at 75mg/m^2 intravenously at the first day in both groups. A course of treatment included 28 days in both groups. Results：The efficacy of treatment group was 37.5% and control group was 42.1% without significant statistically difference between the two groups （ P 〉 0.05 ）. A lower response rate of digestive reaction （ anorexia 22.5% , nausea and vomiting 15.0% ） occurred in treatment group, compared to the control group （anorexia 36.8%, nausea and vomiting 50.0% ） , with a significant difference between the two groups （P 〈 0.05 ）. Hepatotoxicity between two groups was not different but nephrotoxicity of treatment group lowered to control group （7.5 % and 23.7 % , P = 0.05 ）. No difference between two groups in the incidence of leucopenia （37.5 % and 39.5% ,P 〉 0.05 ） and response rate of anemia （47.5% and 52.6%,P 〉 0.05） was found. There was a higher thromboeytopenia response rate in treatment group （47.5%） than in control group （23.7%） with a significant difference between the groups （ P 〈 0.05 ）. Conclusion： There is no significant difference of response rate between nedaplatin and cisplatin regimens, but there are a lower digestive reaction and nephrotoxicity response rate in nedaplatin group. The thrombocytopenia response rate is higher in treatment group but anemia and leueopenia are not different. Nedaplatin is easy to be accepted by patients and doctors.
出处
《现代肿瘤医学》
CAS
2010年第1期81-83,共3页
Journal of Modern Oncology
关键词
奈达铂
顺铂
非小细胞肺癌
nedaplatin
cisplatin
non - small cell lung cancer
